Inmune Bio Inc (INMB) has released an update to notify the public and investors about a regulation fd disclosure.
INmune Bio Inc. announced the FDA has lifted the full clinical hold on its Alzheimer’s disease clinical trial program, with Phase II trial patient enrollment expected to finish by mid-2024. Top line data should be available about six months following the completion of patient enrollment.
For further insights into INMB stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
